Twist Bioscience Corporation Common Stock

Twist's 30.52% short float stands out as notably elevated, suggesting persistent skepticism about the biotech synthetic DNA platform despite a $3.5B valuation. The stock trades near neutral RSI (50.3), indicating neither momentum nor exhaustion, yet lacks a P/E ratio—typical for unprofitable biotech firms betting on future revenue inflection. At 52-week lows, this combination creates potential squeeze dynamics if catalysts emerge, though the high short interest also reflects genuine concerns about execution or competitive threats. The setup favors thesis-driven traders monitoring quarterly burn rates and partnership announcements rather than those seeking traditional value metrics.